Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries C G, Svennerholm L
Department of Psychiatry and Neurochemistry, St. Jörgen Hospital, Hisings Backa, Sweden.
Acta Neurol Scand. 1992 Feb;85(2):103-6. doi: 10.1111/j.1600-0404.1992.tb04006.x.
The myelin-associated glycosphingolipid sulfatide in cerebrospinal fluid (CSF) was investigated in 20 patients with vascular dementia (VAD), 43 with Alzheimer's disease (AD) and 20 age-matched controls. The sulfatide concentration in the VAD group (307 +/- 118 nmol/l) was significantly (p less than 0.0001) higher than that in controls (145 +/- 86 nmol/l) and the AD group (178 +/- 79 nmol/l). Among the VAD patients, 8/20 had a significantly increased concentration of sulfatide (greater than mean + 2 S.D.), as compared with controls, while only 2/43 of the AD patients had a sulfatide concentration above this level. It is suggested that the elevated concentration of sulfatide in CSF from VAD patients reflects demyelination. Furthermore, sulfatide determinations, when combined with clinical findings, may be of diagnostic value, for discriminating between VAD and AD.
对20例血管性痴呆（VAD）患者、43例阿尔茨海默病（AD）患者及20例年龄匹配的对照者的脑脊液（CSF）中髓鞘相关糖鞘脂硫苷脂进行了研究。VAD组的硫苷脂浓度（307±118 nmol/l）显著高于对照组（145±86 nmol/l）和AD组（178±79 nmol/l）（p<0.0001）。在VAD患者中，与对照组相比，20例中有8例硫苷脂浓度显著升高（高于平均值+2标准差），而AD患者中43例仅有2例硫苷脂浓度高于此水平。提示VAD患者CSF中硫苷脂浓度升高反映了脱髓鞘。此外，硫苷脂测定结合临床发现，可能对鉴别VAD和AD具有诊断价值。
